Regenxbio Inc (NASDAQ:RGNX) is one of the best gene therapy stocks to buy in 2026.
On May 14, Regenxbio reported its Q1 2026 financial results and provided operational updates
The company exited the quarter with $150.5 million in cash. The management expects the cash balance to be enough to fund operations into early 2027. Regenxbio has multiple drug development programs underway.
Its RGX-202 gene therapy product candidate returned positive topline results in a Phase 3 study for the treatment of Duchenne. The therapy demonstrated efficacy and was well-tolerated with a favorable safety profile. The company said the topline results support plans for potential accelerated approval of RGX-202 in 2027.